Trial Profile
High Dose Influenza Vaccination and Morbidity and Mortality in U.S. Nursing Homes
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Jul 2020
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Therapeutic Use
- 07 Oct 2018 Results of post hoc analysis evaluating whether a HD trivalent vaccine was associated with a reduced incidence of acute CV events (ACE) among nursing home (NH) residents, compared with a standard-dose trivalent vaccine presented at the IDWeek 2018
- 08 Nov 2017 Planned End Date changed from 1 Dec 2016 to 1 May 2018.
- 30 Oct 2016 Primary endpoint (Hospitalization rate) has been met, according to the results presented at the IDWeek 2016